Renata starts drug shipment to Australia1 min read

Renata, a prominent local pharmaceutical company, has initiated its venture into the Australian market by dispatching its first registered product, Levonorgestrel, under the brand name Novella-1. This move signifies Renata’s commitment to maintaining global standards in its products.

In an official statement, Renata highlighted the significance of this shipment, emphasizing the stringent regulatory requirements of the Australian market. Levonorgestrel, an oral emergency contraceptive pill, holds approvals from esteemed regulatory bodies such as the World Health Organization, the US Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA).

The distribution and commercialization of Levonorgestrel in Australia will be managed by Renata’s partner, Nova Pharmaceuticals Australasia Pty Ltd. Nova Pharmaceuticals has a strong presence in the Australian pharmaceutical market, supplying a wide range of products to pharmacies and supermarkets across the country.

Renata’s decision to introduce Levonorgestrel to the Australian market marks the beginning of a strategic expansion plan. With two additional products awaiting registration in Australia, Renata aims to strengthen its foothold in the global pharmaceutical landscape. This move underscores Renata’s commitment to providing accessible and high-quality healthcare solutions to communities worldwide. As the company continues to navigate the complexities of international markets, its dedication to excellence remains unwavering.

Get real time updates directly on you device, subscribe now.

You might also like
Subscribe
Notify of
guest

0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

0
Would love your thoughts, please comment.x
()
x
SUBSCRIBE TO OUR NEWSLETTER

SUBSCRIBE TO OUR NEWSLETTER

Join our mailing list to receive the latest news and updates from Markedium!

You have Successfully Subscribed!